Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Asset Writedowns and Impairment (2020 - 2025)

Aytu Biopharma (AYTU) has disclosed Asset Writedowns and Impairment for 7 consecutive years, with $800000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 16100.0% to $800000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $9.3 million, a 675.56% increase, with the full-year FY2025 number at $8.3 million, up 588.58% from a year prior.
  • Asset Writedowns and Impairment was $800000.0 for Q4 2025 at Aytu Biopharma, up from $300000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $45.2 million in Q1 2022 to a low of -$200000.0 in Q2 2023.
  • A 5-year average of $5.5 million and a median of $300000.0 in 2025 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 19549.49% in 2021, then plummeted 105.0% in 2024.
  • Aytu Biopharma's Asset Writedowns and Impairment stood at $100000.0 in 2021, then skyrocketed by 2400.0% to $2.5 million in 2022, then crashed by 96.0% to $100000.0 in 2023, then tumbled by 105.0% to -$5000.0 in 2024, then skyrocketed by 16100.0% to $800000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Asset Writedowns and Impairment are $800000.0 (Q4 2025), $300000.0 (Q3 2025), and $8.1 million (Q2 2025).